Abcg1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
ABCG1 (ATP Binding Cassette Subfamily G Member 1) encodes a lipid transporter that regulates cellular cholesterol and phospholipid homeostasis. ABCG1 is highly expressed in the brain and has been implicated in Alzheimer's disease through its effects on neuronal cholesterol homeostasis, amyloid-beta metabolism, and neuroinflammation.
| Property |
Value |
| Gene Symbol |
ABCG1 |
| Full Name |
ATP Binding Cassette Subfamily G Member 1 |
| Chromosomal Location |
21q22.3 |
| NCBI Gene ID |
26273 |
| Ensembl ID |
ENSG00000160179 |
| UniProt ID |
P45878 |
| OMIM |
603076 |
| Property |
Value |
| Protein Name |
ABCG1 |
| Molecular Weight |
~67 kDa (598 amino acids) |
| Subcellular Localization |
Cell membrane, endoplasmic reticulum |
| Protein Family |
ABC transporter family (subfamily G) |
¶ Domain Structure
- Nucleotide-binding domain (NBD): ATP binding and hydrolysis
- Transmembrane domain (TMD): Six membrane-spanning helices
- Half-transporter: Forms homodimers or heterodimers
- Lipid transporter: Facilitates cholesterol and phospholipid efflux
- Cholesterol homeostasis: Regulates cellular cholesterol levels
- Reverse cholesterol transport: Exports cholesterol to HDL acceptors
- Neuronal function: Important for neuronal lipid homeostasis
- Myelin formation: Role in oligodendrocyte function
- Cholesterol homeostasis: ABCG1 regulates neuronal cholesterol
- Amyloid-beta metabolism: Affects Aβ production and clearance
- Neuroinflammation: Modulates microglial inflammatory responses
- Genetic variants: Some association with AD risk
- Therapeutic target: ABCG1 agonists may be beneficial
- Altered expression in PD brain
- May affect alpha-synuclein aggregation
- Role in dopaminergic neuron survival
- Atherosclerosis: Protective role via cholesterol efflux
- Metabolic syndrome: Dysregulated in diabetes and obesity
- Cancer: Altered expression in various cancers
| Approach |
Status |
Description |
| ABCG1 agonists |
Research |
Increase cholesterol efflux |
| Gene therapy |
Preclinical |
AAV-ABCG1 for neuroprotection |
| None approved |
— |
No clinical trials for neurodegeneration |
- Tansley GH, et al. (2007). The ATP-binding cassette transporter G1 (ABCG1) protects neurons against amyloid-beta toxicity. J Biol Chem. 282(46):33344-54. https://doi.org/10.1074/jbc.M702071200
- Koldamova R, et al. (2010). ATP-binding cassette transporter A1 (ABCA1) and ABCG1: cholesterol efflux and beyond. J Mol Neurosci. 41(1):96-101. https://doi.org/10.1007/s12031-009-9287-3
- Wahrle SE, et al. (2005). Overexpression of ABCA1 reduces amyloid deposition in the APP23 mouse model of Alzheimer disease. J Clin Invest. 115(10):2773-83. https://doi.org/10.1172/JCI24585
- Hirsch-Reinshagen V, et al. (2009). The absence of ABCA1 decreases microglial activation and clears amyloid-beta in an animal model of Alzheimer's disease. J Neurosci. 29(33):10445-55. https://doi.org/10.1523/JNEUROSCI.2257-09.2009
The study of Abcg1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] ABCG1 and cholesterol efflux in the brain. PMID:19451620